Related Experiment Videos
Identification and characterization of a lymphocytic Rho-GTPase effector: rhotekin-2
F M Collier1, C C Gregorio-King, T J Gough
1Douglas Hocking Research Institute, Barwon Health, The Geelong Hospital, Geelong, Victoria 3220, Australia. fionac@barwonhealth.org.au
Biochemical and Biophysical Research Communications
|October 27, 2004
Summary
Researchers identified Rhotekin-2 (RTKN2), a novel protein involved in Rho-GTPase signaling. RTKN2 is primarily expressed in T-cells and B-cells, with altered expression in certain leukemias and lymphomas, suggesting a role in lymphopoiesis.
Area of Science:
- Molecular Biology
- Cell Biology
- Immunology
Background:
- Rhotekin proteins are effectors for Rho-GTPases, crucial for cellular signaling.
- A novel gene homologous to human rhotekin was previously identified.
Purpose of the Study:
- To clone and characterize the coding region of the novel rhotekin gene.
- To investigate the expression patterns and splice variants of the new protein, Rhotekin-2 (RTKN2).
Main Methods:
- Cloning and characterization of a 12-exon gene.
- Analysis of the open reading frame (ORF) encoding a 609 amino-acid protein.
- Bioinformatics and RT-PCR to identify splice variants.
- Real-time PCR to determine gene expression in various cell types and conditions.
Main Results:
- The novel protein, Rhotekin-2 (RTKN2), possesses a Rho-binding domain and a pleckstrin homology (PH) domain.
- Three major splice variants of RTKN2 were identified, differing in these domains.
- RTKN2 expression is exclusive to lymphocytes, particularly CD4+ T-cells and B-cells.
- Expression is elevated in quiescent T-cells and significantly altered in various hematologic malignancies.
Conclusions:
- RTKN2 is a novel Rho-binding protein with distinct splice variants.
- Its specific expression in lymphocytes suggests a role in lymphopoiesis.
- Altered RTKN2 expression in malignancies may indicate its involvement in disease pathogenesis.